SPONSORED BY

Auto Segment
Mutual Fund Segment
My Budget
Expert Speak
In Association With
 
Business Standard

Dr Reddy's Lab rises 2.3%

Related News

The stock jumped 2.3 per cent to Rs 1,204.55 after the company said Phase-III clinical trial for its anti-diabetic molecule balaglitazone achieved the set parameters.

The company which conducted the study to determine the efficacy and safety of the drug, with Rheoscience — a subsidiary of said, it met its primary endpoint of reducing HbA1c or Glycoslated haemoglobin molecule, which indicates glucose level in blood. Besides, the oral anti-diabetic drug also showed effective results on fasting plasma glucose, oedeman and weight gain & body composition.

Read more on:   
|

Recommended for you

Quick Links

Market News

Nifty at new-high, Sensex 88 pts shy

Indian markets extend gains for a fourth day

BSE revises annual listing fee of companies for FY16

The exchange has also made changes to various slabs of companies for the payment of listing fees

India seeks trading halts to enable $11 bn of asset sales

India is seeking to suspend trading in shares of companies it plans to sell stakes as part of a plan to raise $11.2 billion from asset sales ...

Milk prices to stay low on skimmed powder inventory

Enough inventory of skimmed milk powder in country will help keeping milk prices under check

Govt may release sugar subsidy payment for last season in two weeks

Will provide a fillip to the raw sugar exports for the current season, mills seek urgent notification for export subsidy

 

Back to Top